10x Genomics, Inc.
TXG
$61.65
$1.672.78%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -12.65% | -2.61% | 0.61% | -1.75% | 12.93% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -12.65% | -2.61% | 0.61% | -1.75% | 12.93% |
| Cost of Revenue | -19.41% | -9.65% | -2.18% | 7.59% | -2.17% |
| Gross Profit | -10.06% | 0.70% | 1.97% | -5.72% | 20.02% |
| SG&A Expenses | 5.68% | -26.02% | -21.26% | -8.63% | -10.36% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -5.17% | -17.46% | -15.01% | -6.52% | -5.83% |
| Operating Income | -117.09% | 64.87% | 67.91% | 23.97% | 74.67% |
| Income Before Tax | -150.40% | 61.66% | 68.60% | 18.10% | 199.78% |
| Income Tax Expenses | -129.04% | -26.88% | 63.43% | -155.74% | 200.61% |
| Earnings from Continuing Operations | -151.92% | 60.80% | 66.85% | 23.16% | 191.14% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -151.92% | 60.80% | 66.85% | 23.16% | 191.14% |
| EBIT | -117.09% | 64.87% | 67.91% | 23.97% | 74.67% |
| EBITDA | -381.73% | 82.50% | 86.06% | 34.67% | 91.58% |
| EPS Basic | -149.41% | 62.53% | 68.28% | 26.07% | 188.43% |
| Normalized Basic EPS | -466.84% | 71.11% | 74.90% | 26.25% | 90.31% |
| EPS Diluted | -150.16% | 62.53% | 68.28% | 26.07% | 187.22% |
| Normalized Diluted EPS | -469.89% | 71.11% | 74.90% | 26.25% | 90.36% |
| Average Basic Shares Outstanding | 5.03% | 4.64% | 4.51% | 3.95% | 3.07% |
| Average Diluted Shares Outstanding | 4.40% | 4.64% | 4.51% | 3.95% | 3.70% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |